Human Live Biotherapeutic Products (LBP) & Microbiome Consortia (GMP)

Why this service exists

Live biotherapeutics are fragile by design. Anaerobes die on contact with oxygen; spores need to be awakened—or not—at exactly the right time; multi-strain consortia must hold their population ratios during blending, storage, and dosing. Most failures in this space are not science problems, they are manufacturability problems: oxygen leaks, off-target moisture, inconsistent CFU enumeration, or uncontrolled overage that collapses shelf life.

Mika Biologics built this LBP CDMO offering to close those gaps. You already know us for Engineered Probiotics (technology depth) and Veterinary & Animal Health (species markets). This human LBP service completes the portfolio for clinical microbiome programs, from strain safety genomics and MCB/RCB under GMP to anaerobic and microaerophilic fermentation, stabilization, enteric delivery, and CMC authoring for IND/IMPD.

Indications and product types we support

• Infectious disease and C. difficile: single-strain spores or defined consortia targeting colonization resistance
• IBD, IBS, and metabolic disease: anti-inflammatory or bile-acid–modulating strains; butyrate producers; mucin degraders with safety fences
• Oncology adjuvant: strains designed to modulate checkpoint therapy responses
• Women’s health and urogenital: Lactobacillus-dominant formulations tuned for pH and bioadhesion
• Neurology and gut–brain axis: candidates with validated metabolite profiles and controlled systemic exposure
• Adjunctive enzyme delivery: engineered or naturally high-titer enzyme producers in LBP chassis
• Consortia: 2–30+ strains with ratio control at release and over shelf life

Each program starts with a QTPP → CQAs → CPPs mapping so clinical intent is explicitly tied to manufacturing and release decisions.

Facility and anaerobic capability

Anaerobic and microaerophilic core

• Organisms: Clostridium, Bacteroides, Akkermansia, Bifidobacterium, Lactobacillus, Faecalibacterium, E. coli Nissle 1917 (non-pathogenic), and selected spore-formers such as Bacillus species under suitable safety profiles
• Infrastructure: anaerobic glove boxes and chambers with trace O₂ monitoring; nitrogen and CO₂ gassing at bioreactor, harvest, and fill steps; low-O₂ single-use flow paths
• Bioreactors: stainless and single-use, 2–500 L process development to clinical scale. Closed-loop pH, temperature, and agitation; redox control via gas mix and media chemistry; resazurin-based monitoring where appropriate
• Media and feeds: chemically defined or complex; carbohydrate and nitrogen optimization; antioxidants and reducing agents such as cysteine and sodium thioglycolate validated for each strain
• Containment and segregation: dedicated rooms for strict anaerobes; spore versus non-spore segregation; unidirectional flow; changeover SOPs with cleaning validation

Process flow (strain evaluation → MCB/RCB → fermentation → downstream and stabilization → formulation and delivery → release)

1. Strain evaluation and safety genomics

• Identity and purity: whole-genome sequencing or 16S rRNA, MALDI-TOF as needed; plasmid status; prophage assessment
• AMR and virulence: in-silico screening, wet-lab antibiogram, absence of key virulence determinants
• Phenotype: growth kinetics, oxygen tolerance, sporulation where applicable, metabolite profile including SCFAs and bile salt metabolism, stress tolerance to acid and bile
• Manufacturability: CFU yield, shear sensitivity, preferred carbon sources, downstream compatibility

2. MCB and RCB under GMP

• Banking: Master Cell Bank and Research or Working Cell Banks at qualified sites, bank size matched to program horizon
• Characterization: identity, purity, stability, antibiogram, absence of adventitious agents, optimized thaw and revival SOPs, storage at ≤ −70 °C or liquid nitrogen

3. Anaerobic and microaerophilic fermentation

• Controls: pH set-points (often 6.5–7.0), temperature (commonly 30–37 °C), DO and redox trending under inert gas overlay, fed-batch for high biomass without acid crash
• Sporulation when applicable: two-stage regimes and media toggles to induce spore formation without compromising downstream recovery
• In-process testing: OD to CFU correlation curves, metabolite titers, off-gas analytics, contamination checks

4. Downstream and stabilization

• Harvest and wash: low-shear centrifugation or TFF; introduction of cryoprotectants such as trehalose, sucrose, skim milk, inulin, or maltodextrin
• Stabilization routes
  • Lyophilization: cycle development including freezing ramp and primary and secondary dry, residual moisture and water activity set for target shelf life
  • Spray-dry: inlet and outlet temperature windows to balance throughput with cell viability, matrix optimization to protect during atomization
  • Microencapsulation: alginate or polymeric matrices for gastric protection depending on program needs
• Moisture and oxygen control: barrier films, foil-foil blisters, oxygen absorbers and desiccants with validated packaging lines

5. Formulation and delivery

• Dosage forms: hard-shell capsules, sachets, and stick packs; liquid suspensions in narrower use cases with stabilizers
• Enteric protection: HPMC-AS, Eudragit L or S, or equivalents; dissolution pH targets aligned to route
• Dose setting: label claim CFU per strain and total CFU, overage strategy to account for process loss and shelf-life decay, blend uniformity acceptance criteria
• Consortia blending: low-O₂ ribbon or bin blending, qPCR or dPCR and plate counts to verify per-strain ratios, segregation studies to prevent demixing

6. Release and stability

• Release testing: identity and CFU per strain, total CFU, purity, endotoxin where applicable, antibiogram, absence of virulence factors, residual moisture and water activity, appearance, packaging integrity
• Stability: real-time and accelerated at target storage (2–8 °C or controlled ambient for spore products), shipping studies for summer and winter lanes and vibration profiles

What we deliver (scope recap)

• Strain evaluation including safety genomics and AMR screening, MCB and RCB under GMP
• Anaerobic and microaerophilic fermentation for Clostridium, Bacteroides, Lactobacillus, Bifidobacterium, E. coli Nissle, and selected Bacillus species
• Downstream and stabilization with cryoprotectants, lyophilization or spray-dry, enteric coatings, capsules or sachets
• Release testing for identity and CFU, purity, endotoxin, antibiogram, absence of virulence factors, and full stability and shipping validation
• CMC for IND and IMPD, Phase I and II supply, consortium blending and potency control

QTPP → CQA → CPP: design for clinical success

QTPP examples

• Indication and route such as oral capsules or sachets and local delivery
• Dose per day and dose duration
• Storage target such as 2–8 °C versus controlled room temperature for spores
• Desired colonization or transient residency, safety margin, and AMR stance
• Presentation in single-dose versus multi-dose packs and child-resistant options

CQAs

• Identity and purity per strain using WGS, 16S, or MALDI
• Potency as CFU per strain and total CFU at release and end of shelf life
• Consortium ratios with relative abundance maintained within specification
• Safety including antibiogram, absence of targeted virulence determinants, endotoxin when applicable
• Physical attributes including residual moisture, water activity, capsule dissolution and enteric performance
• Stability including viability decay rate, resistance to temperature excursions, and packaging integrity

CPPs

• Fermentation parameters including pH set-points, temperature, gas composition and flow, feed strategy
• Harvest and wash including shear exposure, cryoprotectant timing and concentration
• Stabilization including lyophilization shelf temperature and chamber pressure, spray-dry inlet and outlet temperature and solids, target residual moisture
• Blending including time, rpm, atmosphere, and order of addition for multi-strain lots
• Coating and encapsulation including polymer grade, weight gain percent, curing conditions
• Packaging including foil barrier specification, desiccant type and charge, oxygen scavenger capacity

This explicit mapping prevents lab-only success and anchors microbiome CDMO decisions to your clinical objectives.

Analytical and QC panel

Identity and purity

• Whole-genome sequencing for definitive identity and genome stability checks, 16S for routine confirmation
• MALDI-TOF or biochemical panels for orthogonal confirmation
• Microbial purity using aerobic and anaerobic plates, selective media for typical contaminants

Safety and AMR

• Antibiogram with MICs per strain against a targeted panel, genotypic AMR screening, absence of red-flag determinants
• Virulence factor absence verified for target genes such as hemolysins and enterotoxins

Potency and ratios

• CFU enumeration per strain using selective agar or differential methods and total CFU
• qPCR or dPCR for relative abundance when plate counts cannot discriminate
• Blend uniformity through multi-site sampling and statistics

Physical and release attributes

• Residual moisture and water activity, capsule dissolution and enteric performance by pharmacopeial methods
• Endotoxin where applicable, bioburden, and sterility for drug product if required by presentation
• Packaging integrity with headspace oxygen measurement for oxygen-sensitive products

Stability

• Real-time and accelerated studies, temperature excursion robustness, shipping validation with data loggers and seasonal profiles

For deeper method detail, see Analytical & QC.

Formulation and delivery built for survival

• Enteric capsules and coatings using HPMC-AS and Eudragit systems with dissolution at intestinal pH and weight gain tuned to protect through gastric phase
• Cryo- and lyo-protectants such as trehalose, sucrose, skim milk, inulin, and mannitol selected by DoE to maximize post-process viability
• Sachets and stick packs using high-barrier foil laminates with desiccant integration and oxygen scavengers for ultra-low O₂ headspace
• Multi-strain rules that prevent antagonism by staggering additions, using compatible matrices, and confirming no bacteriocin-driven kill within the blend
• Overage logic that models decay with Arrhenius where applicable and sets overage to meet end-of-shelf-life CFU without risking early capsule swelling or gas formation

For aseptic presentation or hybrid processes, visit Formulation & Aseptic Fill-Finish.

Scale and cold chain

Typical scales

• Development non-GMP: 2–20 L fermentation for feasibility and formulation screens
• GMP Phase I and II: 50–500 L per strain, batch or staggered schedule for consortia

Cold chain

• Frozen intermediates at ≤ −70 °C for bulk wet cakes or concentrated slurries prior to lyophilization
• Finished drug product at 2–8 °C for most non-spore products, controlled ambient feasible for spore-formers with validated packaging
• Shipping with qualified lane profiles, phase-change materials, and data-logged excursions with predefined acceptance criteria

Regulatory and CMC for IND and IMPD

• Classification as LBPs that are drugs or biologics in US and EU. Operations aligned to 21 CFR 210 and 211, ICH Q8, Q9, and Q10, and applicable pharmacopeial methods
• CMC authoring package
  • Process description with flow diagrams from bank to seed, fermentation, stabilization, blending, and packaging
  • Materials and suppliers with specifications, COAs, change control alignment, and traceability
  • Batch records with in-process controls and hold times
  • Specifications for identity, purity, CFU per strain, safety attributes, dissolution and enteric performance, packaging
  • Methods and validation or qualification plan for ID and CFU, qPCR ratios, moisture and water activity, dissolution, and safety assays
  • Stability protocol, acceptance criteria, shelf-life assignment, and shipping stability
  • Comparability for scale or equipment changes, formulation or coating changes, and strain additions or removals in consortia

We collaborate with your regulatory team to align dossier language and responses.

Tech transfer and risk controls

Tech transfer

• Receive strain dossier, historical culture conditions, prior CFU curves, and safety findings; perform gap analysis and design bridging steps
• Align banking strategy for MCB and RCB and create a reference standard

Risk controls

• Anaerobic discipline with oxygen control plans at every unit operation, leak-tested closures, in-line oxygen monitoring, and nitrogen-flooded holds
• Cross-contamination control through spore versus non-spore segregation, validated cleaning, and environmental monitoring trend reviews
• Enumeration variability management with harmonized selective media, SOPs for thaw-to-plate timing, and inter-operator reproducibility checks
• Consortia drift control using low-oxygen blending, anti-segregation studies, per-strain overage calibration, and ratio monitoring with qPCR or dPCR and plating

Case studies (anonymized)

A. Anaerobic consortium for IBD with six strains
Challenge: three strict anaerobes with oxygen shock at harvest and ratio drift after three months
Solution: nitrogen-flooded harvest and wash, trehalose-rich lyo blend, bin blending under less than 0.5 percent oxygen, ratio monitoring by dPCR
Outcome: release within plus or minus 10 percent per-strain target and 12-month 2–8 °C stability with less than 0.5 log total CFU loss

B. Spore-former for prevention of recurrent infection as a single strain
Challenge: spray-dry viability loss at required throughput
Solution: inlet and outlet temperature re-balancing, two-step atomization trial, protective matrix switch to inulin and maltodextrin
Outcome: 1.2 log CFU improvement and controlled-ambient stability in foil-foil blisters with desiccant

C. E. coli Nissle drug product in sachets
Challenge: high initial potency but rapid moisture-driven decay in paper–poly sachets
Solution: switch to alu-alu laminate, internal desiccant, water activity specification at or below 0.2 at release, overage modeled by Arrhenius fit
Outcome: 18-month shelf life at 2–8 °C with no caking or gas formation

FAQs

1. Can you bank our strains under GMP
   Yes. MCB and RCB with full characterization including identity, purity, AMR and virulence screens, and revival SOPs.
2. How do you quantify per-strain potency in consortia
   Selective plating where feasible; otherwise qPCR or dPCR with validated primers and plate counts for total CFU.
3. Do you support enteric coatings and capsule formats
   Yes. HPMC-AS and Eudragit systems with dissolution at target pH; capsules, sachets, or stick packs.
4. What storage can I expect
   Most non-spore LBPs at 2–8 °C. Spores can be room-temperature with proper barrier packaging and desiccants. Shelf life is data-driven.
5. How do you manage oxygen exposure
   Nitrogen and CO₂ blankets, low-oxygen chambers, monitored headspace oxygen, and validated closures at every step.
6. Can you run spray-dry and lyophilization
   Yes. Cycle development for both, with matrix and process DoE to balance viability, throughput, and residual moisture.
7. What about endotoxin and sterility
   We test endotoxin where the route demands it; drug product sterility is presentation-specific. Bioburden limits and environmental monitoring are standard.
8. Can you add or remove a strain mid-program
   Yes, with a comparability plan and risk assessment that includes ratio re-definition, analytics updates, and labeling revisions.
9. How do you handle AMR concerns
   We run antibiograms and genomic screens and avoid problematic determinants. Documentation is included in CMC.
10. Do you assist with IND and IMPD drafting
    Yes, complete CMC authoring and responses in collaboration with your regulatory team.

How to engage

1. Discovery call to align on indication, route, dose, and QTPP
2. Feasibility design with strain dossier review and a manufacturability and analytics plan
3. Workplan and quote with milestones from banking to drug product release, decision gates, and lead times
4. Kickoff with material readiness, tech transfer, and risk register

Summary

Live biotherapeutics demand a CDMO that speaks both microbiology and manufacturing. As your LBP CDMO, Mika Biologics delivers a complete path from safety genomics and GMP banking through anaerobic fermentation, stabilization by lyophilization or spray-dry, enteric delivery, and CMC that regulators can trust. Whether you are advancing a single spore-former or a 20-strain consortium, we design with QTPP first, lock CQAs that matter, and control the CPPs that move them so your product survives the plant, the pack, the truck, and the gut.